| Name | Title | Contact Details |
|---|
RAPS is the largest global organization of and for those involved with the regulation of healthcare and related products, including medical devices, pharmaceuticals, biologics and nutritional products.
Cardinal Health, Inc. is an American multinational health care services company, and the 14th highest revenue generating company in the United States.
Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of Aramchol, a novel, once-daily, oral therapy for treating liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Aramchol is initially being developed for treating Non-Alcoholic Steato-hepatitis, or NASH, a chronic disease affecting a large population, for treating patients who also suffer from obesity and insulin resistance. Galmed Pharmaceuticals Galmed’s business has been, in its current legal structure, was incorporated in Israel on July 31, 2013 as a privately held company. However, operating since 2000 under a different group of companies established in the same year. Galmed was co-founded by Professor Tuvia Gilat and Allen Baharaff, based on Professor Gilat’s extensive research in FABAC’s and NASH.
Scientia Vascular offers access devices (microcatheters / guidewires) and therapies that are optimized to address the evolving needs of interventional specialists. Learn more about our next-generation solutions.